loading

Ausovi pioneers the design and synthesis of advanced analog compounds, bridging cutting-edge science and strategic partnerships to unlock new therapeutic possibilities for global health.

Contact Info

+1 949 382-515x
Our Structured Journey to Breakthrough Analogs
Our Path to Analog Therapeutics

Year 1-2

Discovery Ignition

Ausovi identifies unmet needs and engineers initial analog structures via computational modeling and target validation. Early IP filings secure core compositions, laying the foundation for proprietary innovation.

Years 3–4

Molecular Refinement

Promising analogs undergo iterative optimization through precise chemical synthesis and structure-activity analysis. In-house and collaborative efforts yield high-purity candidates with enhanced specificity and stability.

Years 5–6

Preclinical Validation

Rigorous in vitro/in vivo testing evaluates pharmacokinetics, efficacy, and safety profiles. Robust data generation supports expanded IP claims and proof-of-concept, positioning compounds for advanced development or strategic opportunities.

Years 7+

Portfolio Maturation

Validated analogs integrate into Ausovi’s growing portfolio of life-changing therapeutics. Continued refinement, regulatory preparation, and partnership exploration accelerate paths to clinical translation and broader medical impact.

  • Analog Design & Modeling
  • Synthesis & Optimization
  • Preclinical Validation
  • IP & Portfolio Strategy
  • Analog Design & Modeling
  • Synthesis & Optimization
  • Preclinical Validation
  • IP & Portfolio Strategy

LEARN MORE

    Send Message